Ligand Pharmaceuticals, Inc. Income Statement
LGND / Health Care|15 years of annual SEC 10-K data (FY2011-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 15 fiscal years. All figures from audited SEC 10-K filings.
Ligand Pharmaceuticals, Inc. reported $268M in revenue and $124M in net income for FY2025. Revenue has grown at a 16.9% compound annual rate over the past 14 years.
Based on SEC 10-K filings.
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $268.1M | $167.1M | $131.3M | $196.2M | $241.5M | $163.6M | $120.3M | $251.5M | $29.3M | $109.0M | $71.9M | $64.5M | $49.0M | $31.4M | $30.0M |
| Cost of Revenue | - | - | - | - | - | - | - | $6.3M | $5.4M | $5.6M | $5.8M | $9.1M | $5.7M | $3.6M | $4.9M |
| SG&A Expense | $92.4M | $78.7M | $52.8M | $70.1M | $46.8M | $60.0M | $41.9M | $37.7M | $28.7M | $27.7M | $25.4M | $22.6M | $18.0M | $15.8M | $14.6M |
| R&D Expense | $81.2M | $21.4M | $24.5M | $36.1M | $32.1M | $40.5M | $55.9M | $27.9M | $26.9M | $21.2M | $11.0M | $9.7M | $9.3M | $10.8M | $10.3M |
| Operating Income | $41.0M | -$22.6M | $11.9M | $3.0M | $103.9M | $37.5M | $807.1M | $163.7M | $68.1M | $43.9M | $27.3M | $19.6M | $14.9M | $193.0K | -$878.0K |
| Interest Expense | - | - | $656.0K | $1.8M | $19.6M | $27.4M | $35.7M | $48.3M | $13.5M | $12.8M | - | $4.9M | $2.1M | $2.9M | $2.5M |
| Income Tax | $34.5M | $6.5M | $9.8M | $41.2M | -$4.1M | -$5.3M | $167.3M | $30.0M | $44.7M | $10.3M | -$192.1M | $410.0K | $374.0K | -$1.2M | -$13.3M |
| Net Income | $124.5M | -$4.0M | $52.2M | -$33.4M | $57.1M | -$3.0M | $629.3M | $143.3M | $12.6M | -$1.6M | $229.8M | $12.0M | $11.4M | -$527.0K | $9.7M |
| EPS (Basic) | $3.02 | -$1.98 | $3.44 | -$0.18 | $33.13 | $6.77 | $0.60 | -$0.08 | $11.61 | $0.59 | $0.56 | -$0.03 | $0.49 | - | - |
| EPS (Diluted) | $2.94 | -$1.98 | $3.31 | -$0.18 | $31.85 | $5.96 | $0.53 | -$0.08 | $10.83 | $0.56 | $0.55 | -$0.03 | $0.49 | -$0.53 | -$0.10 |
| Shares Outstanding | 19.1M | 17.6M | 17.0M | 16.8M | 16.1M | 16.8M | 20.8M | 21.1M | 20.9M | 19.9M | 19.6M | 20.5M | 21.3M | 20.7M | 18.9M |
| Operating Margin | 15.3% | -13.5% | 9.1% | 1.6% | 43.0% | 22.9% | 671.0% | 65.1% | 232.6% | 40.3% | 38.0% | 30.4% | 30.5% | 0.6% | -2.9% |
| Profit Margin | 46.4% | -2.4% | 39.7% | -17.0% | 23.7% | -1.8% | 523.2% | 57.0% | 42.9% | -1.5% | 319.6% | 18.6% | 23.3% | -1.7% | 32.3% |